TP53 and neoplasm: This review reframes immunotherapy in colorectal cancer (CRC) from a binary paradigm to an integrated, biology-driven model in which TP53 functions as a contextual modifier alongside tumor mutational burden (TMB) and the tumor microenvironment (TME).